Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
Rodríguez-Lescure, A. (Hospital General Universitario de Elche)
de la Peña, F. A. (Hospital General Universitario Morales Meseguer (Múrcia))
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Calvo, A. (Hospital General Universitario Gregorio Marañón)
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Vera, Ruth (Complejo Hospitalario de Navarra)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.
Nota:	Altres ajuts: This study was funded by SEOM.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Oncology ; Drug ; Biomarker ; Equity ; Access ; Barriers ; Spain
Publicado en:	Clinical & translational oncology, Vol. 22 (june 2020) , p. 2253-2263, ISSN 1699-3055

DOI: 10.1007/s12094-020-02366-y
PMID: 32533318

11 p, 515.9 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados